The Title of Reporting Person: SVP, Finance and Admini of Puma Biotechnology (PBYI) is Selling Shares


Today, the Title of Reporting Person: SVP, Finance and Admini of Puma Biotechnology (PBYI), Charles Eyler, sold shares of PBYI for $25.01K.

In addition to Charles Eyler, one other PBYI executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Puma Biotechnology’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $62.63 million and GAAP net loss of $14.2 million. In comparison, last year the company earned revenue of $21.6 million and had a GAAP net loss of $64.1 million. Currently, Puma Biotechnology has an average volume of 981.9K. The Company has a Price to Book ratio of 17.2470.

Based on 8 analyst ratings, the analyst consensus is Hold with an average price target of $40.50, reflecting a 89.4% upside. Three different firms, including Barclays and Merrill Lynch, currently also have a Sell rating on the stock.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts